Holen Sie sich die Stockscreener-App
291.77
0.11%
-0.32
Handel nachbörslich:
293.51
1.74
+0.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen Stock (AMGN) Opinions on Recent Price Dip and Drug Approvals - Quiver Quantitative
Strategic Financial Services Inc. Purchases Shares of 1,217 Amgen Inc. $AMGN - MarketBeat
General American Investors Co. Inc. Sells 5,000 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by New York Life Investment Management LLC - MarketBeat
Amgen Inc. $AMGN Stock Holdings Lowered by GWN Securities Inc. - MarketBeat
Y Intercept Hong Kong Ltd Buys 7,370 Shares of Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Has $7.16 Million Stake in Amgen Inc. $AMGN - MarketBeat
What dividend safety score for Amgen Inc. stockWeekly Market Report & Long Hold Capital Preservation Tips - newser.com
Is Amgen Poised for Growth After Recent 4% Price Dip? - simplywall.st
Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline - Yahoo Finance
Does Amgen Inc. fit your quant trading modelTrade Exit Summary & Verified Chart Pattern Trade Signals - newser.com
Amgen Inc. stock daily chart insightsJuly 2025 Spike Watch & Accurate Buy Signal Alerts - newser.com
How supply shortages influence Amgen Inc. (AMG) stock2025 Dividend Review & Verified Entry Point Signals - newser.com
Trust Investment Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Howard Capital Management Inc. Has $5.86 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Motley Fool Asset Management LLC Acquires 2,924 Shares of Amgen Inc. $AMGN - MarketBeat
Logan Capital Management Inc. Reduces Holdings in Amgen Inc. $AMGN - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $30.26 Million Position in Amgen Inc. $AMGN - MarketBeat
Will Amgen Inc. (AMG0) stock extend growth storyWeekly Volume Report & Technical Analysis for Trade Confirmation - newser.com
Teacher Retirement System of Texas Sells 8,974 Shares of Amgen Inc. $AMGN - MarketBeat
Transcend Capital Advisors LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Is Amgen Inc. (AMG0) stock undervalued after correctionWatch List & Capital Efficiency Focused Strategies - Fundação Cultural do Pará
Should I buy Amgen Inc. (AMG0) stock before earnings seasonWeekly Trade Review & Daily Chart Pattern Signal Reports - newser.com
What Fibonacci levels say about Amgen Inc. rebound2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Is Amgen Inc. (AMG) stock protected from inflation2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
Why Amgen Inc. (AMG) stock could be top winnerQuarterly Portfolio Summary & Real-Time Chart Breakout Alerts - Fundação Cultural do Pará
Amgen (AMGN) Expected to Announce Earnings on Tuesday - MarketBeat
Using flow based indicators on Amgen Inc.2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
What is the fair value estimate for Amgen Inc. (AMG) stock in 2025Weekly Profit Summary & Fast Gain Stock Tips - newser.com
Will Amgen Inc. (AMG0) stock profit from AI boom2025 Market Sentiment & AI Forecast Swing Trade Picks - newser.com
Will Amgen Inc. (AMG0) stock recover faster than industry2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Will Amgen Inc. (AMG0) stock outperform energy sector in 2025July 2025 Institutional & Weekly Top Performers Watchlists - newser.com
Amgen’s Promising Phase 3 Study on Blinatumomab for Leukemia: What Investors Need to Know - TipRanks
Amgen’s Long-term Study on Dazodalibep: A Potential Breakthrough for Sjögren’s Syndrome - TipRanks
Amgen’s Phase 2a Study on Autoimmune Diseases: A Potential Game-Changer? - TipRanks
Amgen’s Apremilast Study: A Potential Game-Changer for Pediatric Behçet’s Disease - TipRanks
Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s Innovative Study on AMG 193: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen’s AMG 509 Study: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Amgen’s Romiplostim Study: A Potential Game-Changer for Cancer Treatment - TipRanks
Amgen’s Latest Clinical Study Update: A New Hope for Small Cell Lung Cancer? - TipRanks
Amgen’s Apremilast Study: A New Hope for Pediatric Patients - TipRanks
Amgen’s New Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Amgen’s AMG 410 Study: A Potential Game-Changer in KRAS-Altered Tumor Treatment - TipRanks
Amgen’s New Study on Xaluritamig: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
Amgen’s Prolia Study: A New Horizon for Male Osteoporosis Treatment in China - TipRanks
Amgen’s Promising Study on Romosozumab for Osteogenesis Imperfecta: A Potential Game-Changer - TipRanks
Amgen’s AMG 355 Study: A Potential Game-Changer in Oncology? - TipRanks
Amgen’s Promising Phase 3 Study on Metastatic Colorectal Cancer - TipRanks
Amgen’s Phase 2 Study on Tarlatamab: A Potential Game-Changer for SCLC Treatment - TipRanks
Amgen’s Pediatric NMOSD Study: A Potential Game-Changer? - TipRanks
Amgen’s Maridebart Cafraglutide: A New Hope for Cardiovascular Health? - TipRanks
Amgen’s Repatha® Study: A Potential Game-Changer in Cardiovascular Care - TipRanks
Amgen’s Latest Clinical Study: A Potential Game-Changer in Lung Cancer Treatment - TipRanks
Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment - TipRanks
Amgen’s Prolia® Study: A New Frontier in Osteoporosis Treatment - TipRanks
Amgen’s Sotorasib Study: A Real-World Evaluation in Chinese NSCLC Patients - TipRanks
Amgen’s Phase 3 Study on Rocatinlimab: A Potential Game-Changer for Prurigo Nodularis - TipRanks
Amgen’s AMG 193 Study: A Potential Game Changer for MTAP-null Solid Tumors - TipRanks
Amgen’s Pediatric Psoriasis Study: A Potential Game-Changer in Dermatology - TipRanks
Amgen’s Latest Study: A New Contender in Lung Cancer Treatment? - TipRanks
Amgen’s AMG 193 Study: A New Hope for Advanced NSCLC Treatment? - TipRanks
Amgen’s New Melanoma Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Amgen’s Xaluritamig Trial: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Amgen’s Latest Study on Sotorasib: A Strategic Move in Oncology - TipRanks
0.53%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):